tiprankstipranks
Trending News
More News >

Kadimastem Enters Licensing Agreement with NLS Pharmaceuticals

Story Highlights
Kadimastem Enters Licensing Agreement with NLS Pharmaceuticals

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Kadimastem ( (IL:KDST) ) is now available.

Kadimastem Ltd has announced a significant licensing agreement with NLS Pharmaceuticals Ltd. This deal is expected to impact Kadimastem’s business activities, potentially aiding in capital raising efforts and enhancing their market positioning.

More about Kadimastem

YTD Price Performance: 48.62%

Average Trading Volume: 15,684

Current Market Cap: ILS74.9M

See more insights into KDST stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1